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The blood beryllium lymphocyte proliferation test (BeLPT) is an in vitro measure of the beryllium
antigen-specific cell-mediated immune response. This response to beryllium is now understood
to play a central role in the immunopathogenesis of chronic beryllium disease (CBD). Although
there remain some unresolved methodologic issues with testing, the blood BeLPT has already
undergone sufficient development and field assessment to lead to a number of important
conclusions: a) The BeLPT identifies beryllium sensitization and CBD earlier and better than any
other clinical test presently available. b) The CBD cases identified with the blood test are clinically
significant. c) A subset of the people identified by the BeLPT who do not yet have clinical disease
will progress and require treatment with corticosteroids for impairing illness. d) The BeLPT can be
used to improve clinical diagnostic accuracy and to correct mistaken diagnoses. e) The blood test
can be used in screening large numbers of exposed workers because it is sensitive and specific
and has high positive and negative predictive value for CBD. f) In every workforce studied to
date, the BeLPT has identified beryllium sensitization and CBD that had been missed by
conventional screening efforts. g) Worker populations that have been characterized using the
BeLPT can help to elucidate the role of exposure genetics and dysregulated inflammation in the
genesis of occupational lung disease. Environ Health Perspect 104(Suppl 5):953-956 (1996)
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Introduction
The first clinical demonstration of the
immunologic basis of chronic beryllium
disease (CBD) occurred in the 1950s when
researchers showed that beryllium salts
could elicit a typical delayed-type hyper-
sensitivity reaction (1,2). While applica-
tion of the beryllium fluoride patch test
showed that it was possible to identify
individuals who were sensitized to beryl-
lium and who had CBD, skin testing has
not been widely used in the United States
since the 1960s because of concern that
such testing could either exacerbate disease
or induce sensitization (3). Patch testing is
both time consuming and impractical as a
screening test, and has since been supplanted
by other methods of detecting the cell-
mediated immune response to beryllium.
In 1970, Hanifin and colleagues
demonstrated that blood cells obtained from
patients who had positive beryllium patch
tests would proliferate in vitrowhen stimu-
lated with beryllium sulfate or oxide (4).
Their work set the stage for the next 25
years of research into the utility of in vitro
assays for detecting CBD. Other investiga-
tors verified their observation of a cell-
mediated immune response to beryllium
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both in the blood and in cells retrieved
from the lung via bronchoalveolar lavage
(5-15). The lymphocyte response to beryl-
lium in these cell cultures is specific for
beryllium salts and specific for CBD, form-
ing the basis for use of lymphocyte prolif-
eration as a clinical tool, as discussed below
(12,14,15). The immunopathogenesis and
the role of cell-mediated immunity in
CBD have been the subjects of two recent
reviews (16,17).
CBD illustrates how our increased
understanding of immunology can lead to
clinical application. As shown in Table 1,
immunologic assessment of beryllium sen-
sitization provides diagnostic information,
serves as a biomarker for screening large
numbers of exposed workers for disease,
and has made it possible to examine the role
of occupational exposure and of genetic
predisposition in the development ofoccu-
pational disease. Blood lymphocyte prolifer-
ation testing for beryllium sensitization has
revolutionized both the clinical and research
approaches to CBD in the last decade.
Development of Methods
Although the first in vitro observations of
beryllium-specific cell proliferation were
made in the 1970s, it was not until the
early 1980s that the first studies were done
to test whether the blood BeLPT could be
used as a clinical diagnostic tool (7,8,10).
Initial studies from the United Kingdom
demonstrated that while the blood test
could detect individuals with beryllium
sensitization and disease, it was too insensi-
tive and too difficult to reproduce for clini-
cal use. The test fell out offavor until our
group reevaluated the test parameters,
made additional efforts to optimize culture
conditions, and then field tested the BeLPT
at a nuclear weapons plant (13,15,18). We
demonstrated that by further optimizing
assay conditions using a radiolabeled DNA
precursor (tritiated thymidine) as the
marker ofproliferation, the blood test can
be made more easily reproducible and vali-
dated as a superior means ofdetecting dis-
ease. The assay, as used today, relies on
mononuclear cells isolated from hepari-
nized venous blood. The cells are placed in
primary culture, in the presence and
absence ofberyllium sulfate, across a three-
log range ofsalt concentrations. Cell prolif-
eration is measured by the incorporation of
the tritiated thymidine into the dividing
cells after 3, 5, and 7 days in culture. Cells
are harvested from microtiter plates and
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Table 1. Significance ofthe blood beryllium lymphocyte proliferation test.
Type of assessment Function Potential advantages
Diagnosis Screen clinical cases for CBD Recognition of disease in new
Correct mistaken diagnoses of sarcoidosis segments ofthe beryllium industry
and interstitial lung disease
Improve diagnostic accuracy overthe
available tests
Identify individual cases of CBD as "sentinel
health events"
Workplace screening Improve sensitivity over other available High positive and negative
screening tools (e.g., chestX-ray, spirometry, predictive value
symptom reporting, physical examination)
Improve specificity over other available tests
Early detection of beryllium sensitization Possibility for early intervention
(sensitized individuals develop CBD)
Early detection of CBD (subclinical cases Possibility for early intervention
progress to clinical CBD)
Identify individuals with clinically active CBD
who have been misdiagnosed and incorrectly
treated
Targeting engineering control efforts Reduce exposure of beryllium
workers and others
Research Epidemiologic investigations Identify high-riskworktasks,
high-risk exposures, and personal
risk factors in the workplace
Immunogenetic investigations Population-based examination of
genetic riskfactors and their
association with exposure
Development of new biomarkers ofdisease risk,
activity, severity, or response to therapy
Facilitate in vitrostudies of immunologic and
inflammatory mechanisms (e.g., T-cell and
macrophage cytokine release and dysregulation)
the amount ofradiolabel that has entered
the cells measured in a liquid scintillation
counter. Results are expressed as a "stimu-
lation index": the ratio of the counts per
minute of radioactivity in cells stimulated
by beryllium salts divided by the counts
per minute for unstimulated cells. Each
laboratory sets its own normal range for
the test, based on data from normal nonex-
posed control subjects whose blood has
been tested by the same method.
In reworking the BeLPT, we showed
that the blood test is reproducible between
laboratories, that it can identify 94% of
patients who had abnormal bronchoalveo-
lar (BAL) BeLPT plus granulomatous lung
pathology (CBD), and that it reliably
identifies patients with CBD at very early
stages ofdisease or when they are sensitized
and on their way to developing clinical dis-
ease (15,19). Subsequent work with the
test suggests that it detects somewhat less
than 94% of cases. Further efforts to stan-
dardize the assay have been undertaken by
several laboratories, with varying success.
The BeLPT, like other cell culture
assays, is associated with significant intra-
test, intertest, and interlaboratory variabil-
ity. The BeLPT's "growing pains" are in
evidence at this conference, as industry has
encouraged multiple laboratories to quickly
increase the volume of testing at multiple
centers. Laboratories continue to differ in
their ability to identify cases of CBD
because ofvariability in serum, culture
conditions, methods of cell harvesting,
radiolabel counting, and data analysis; and
lack of consistent positive control in each
assay. Thus, it is advisable that prior to
launching a clinically invasive evaluation
for CBD based on an abnormal blood
BeLPT, the positive test should be recon-
firmed with a second venipuncture sample
(16). The technical challenges ofthe blood
BeLPT do not negate the observations that
the test detects beryllium sensitization and
CBD at earlier stages than any other clini-
cal test available (20) and has proven valid-
ity, having been used to detect clinically
significant lung disease, as discussed below.
Blood BeLPT in Diagnosis
Several case series have demonstrated that
the BeLPT, as an indicator ofberyllium-
specific cellular immune response, is abnor-
mal in patients with CBD but not elevated
in normal subjects, beryllium-exposed nor-
mal subjects, beryllium-exposed subjects
with other (nongranulomatous) lung
diseases, and patients with no beryllium
exposure but who have granulomatous dis-
eases such as sarcoidosis and hypersensitiv-
ity pneumonitis (9,11,12,15). Therefore,
the BeLPT can be used to help diagnose
CBD in patients who have compatible
lung pathology, helping to differentiate it
from similar-appearing lung diseases. This
assay has become part of the standard
clinical repertoire in CBD diagnosis
(16,18). Although the test is performed
reliably in only a few centers in the United
States, it can be obtained by shipping
blood via overnight carrier. If handled
properly, blood can be tested up to 24 hours
after venipuncture.
It has been observed that the level
of beryllium stimulation of blood cells is
lower than that seen in BAL cells in many
patients with CBD (9,12,21). This is oflit-
tle significance except that it reflects the dif-
ference in the number ofberyllium-reactive
lymphocytes present in a blood specimen
compared with the pulmonary compart-
ment (21). The blood test is less invasive,
more practical, nearly as predictive ofberyl-
lium-related lung granulomas as BAL
BeLPT, and better standardized (15,16).
Therefore, individuals with suspected CBD
should first be screened with the blood test.
Under certain circumstances, BAL BeLPT
can give false negative results, such as when
there is a marked excess of alveolar macro-
phages in the lavage, e.g., in cigarette
smokers. Blood can be readily shipped in
heparinized tubes to one ofthe laboratories
that performs the BeLPT, whereas BAL
must be centrifuged and the cells resus-
pended in complete culture medium prior
to shipping. Under some circumstances,
such as when there is an abnormal blood
BeLPT and typical clinical, radiographic,
and physiologic findings, it may be reason-
able to diagnose CBD even without biopsy.
Some individuals with CBD may have neg-
ative blood responses, so in instances in
which the index ofsuspicion is high but the
blood BeLPT is normal, BAL and trans-
bronchial lung biopsies should be per-
formed to determine if there is reactivity
to beryllium by lung lymphocytes and
compatible histopathology.
When should clinicians order the
BeLPT? Based on the epidemiologic studies
ofexposed work forces and on clinical case
series, the diagnosis should be considered
in any individual with either direct or
bystander exposure to beryllium. This
includes secretaries, maintenance workers,
security guards, spouses of beryllium
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workers, and others with seemingly trivial
exposure (13,15,18-20,22). CBD can
masquerade as other lung diseases, includ-
ing sarcoidosis (23), pulmonary fibrosis,
hypersensitivity pneumonitis, and asthma.
Thus, the diagnosis should be considered
and the BeLPT drawn in any patient with
lung disease who has had any direct or
indirect contact with beryllium, as elicited
in the occupational or environmental his-
tory. Physicians should not prejudge the
significance of past beryllium exposure
(20,22,23). An abnormal blood BeLPT
proves that the exposure was sufficient to
cause the body's immune system to recog-
nize beryllium as antigenic. The diagnosis
may be missed if the physician assumes
that the exposure was "too low" to cause
disease, assumes that exposure was too
remote, or fails to take a sufficiently detailed
occupational or environmental history
ofexposure.
Blood BeLPT in Screening for
Sensitization and Disease
The BeLPT was assessed in the 1970s as a
potential screening test, but at that time
the read-out was highly subjective, based
on the morphologic appearance of "lym-
phoblasts" in culture (6,24). Reproduci-
bility ofthat method was poor and workers
with abnormal blood tests did not show
spirometric and radiologic abnormalities
suggestive of CBD, leading the investiga-
tors to discard it as a screening test (24).
We now know that spirometry and chest
X-ray were insensitive tools by which
to gauge the ability of the blood test to
identify CBD (13).
Following methodologic improvements
in the assay, the BeLPT was given a fresh
chance in four population-based studies
conducted over the past 9 years. Additional
studies are on-going. Since 1986, the use of
the blood BeLPT has been reported in
screening populations ofworkers from the
nuclear weapons, ceramics, and foundry
industries (11,13,20,22). In a cohort of
beryllium ceramics workers, confirmed
abnormal blood BeLPTs predicted granu-
lomatous lung disease on biopsy in every
case. In the nuclear industry, not all work-
ers with confirmed abnormal tests had
beryllium disease on biopsy at the time of
screening. One-third of those with abnor-
mal blood tests had no granulomas on
biopsy initially, but halfofthis "sensitized-
only" group developed granulomas on
biopsy during a short, 2-year follow-up
period. We conclude that the blood
BeLPT can identify individuals with CBD
and also can identify beryllium-sensitized
individuals who do not have disease but
who are at high risk of developing CBD.
Longitudinal follow-up ofthese groups is
in progress (25).
While our initial BeLPT studies ofthe
active workforce at the nuclear weapons
plant identified many individuals with so-
called "subclinical" or early-stage CBD,
later, more detailed examination of the
pulmonary physiology in these patients
showed that most ofthem had one or more
abnormalities of lung function and gas
exchange even ifthey were only minimally
symptomatic (26). Moreover, since the
nuclear weapons plant started to use the
BeLPT to screen retired workers, many
cases of symptomatic, physiologically
impaired but often misdiagnosed cases of
CBD have been identified. The proportion
ofclinical to subclinical cases may reflect,
in part, the degree to which other screen-
ing tests have been applied. We conclude
that any individual with confirmed abnor-
mal blood BeLPT warrants close examina-
tion for evidence of early disease, that all
pulmonary diagnoses in these patients
should be carefully reexamined because of
the risk ofmisdiagnosis, and that patients
with abnormal blood tests should remain
under medical surveillance due to the risk
ofprogression to clinical illness.
The cross-sectional workforce studies
demonstrate that the BeLPT has higher pos-
itive and negative predictive value for CBD
than other tests conventionally used in
screening beryllium workers, including clin-
ical examination, symptom reporting on
questionnaires, spirometry, and chest radi-
ography (20). These studies also show that
the BeLPT is not perfectly sensitive,
although it is highlyspecific. In both ceram-
ics and nuclear worker cohorts we identified
cases ofCBD among some individuals with
abnormal chest radiographs who had nor-
mal blood BeLPTs. A negative blood test
does not fully exclude CBD. Recent evi-
dence suggests that exposed workforces
should undergo periodic rescreening with
the BeLPT because additional cases will be
detected. This may reflect either the imper-
fections in the BeLPT or newly emerging
sensitization due to on-going exposure,
changes in host immunity, or other factors
affecting immune responsiveness.
The BeLPT as a Catalystfor
Research on Exposure,
Mechanism, and Prevention
The merit ofa biomarker ofdisease hinges
on whether the consequence being
identified results in the prevention of dis-
ease. The screening of large numbers of
beryllium-exposed individuals may lead to
secondary and tertiary prevention. Patients
who are sensitized or who have CBD can
receive earlier treatment and may be less
likely to progress to end-stage fibrosis, cor
pulmonale, and death. Preliminary evi-
dence from an on-going longitudinal study
ofthese patients indicates that earlier inter-
vention with corticosteroids helps reduce
morbidity and may prevent progression to
end-stage disease (25). Confirmation of
this hypothesis merits formal study.
The use ofthe blood BeLPT in popula-
tion-based studies has opened the door to
two fruitful areas ofinvestigation that may
lead to primary prevention: studies of the
relation between exposure and disease and
studies of the relation ofgenetics to expo-
sure. Such research avenues could not have
been pursued effectively until large num-
bers ofworkers were screened with the
BeLPT. Knowing who is sensitized and
diseased has enabled us to begin to exam-
ine three important questions: a) What is
different about beryllium exposure for
those who develop sensitization and disease
than for those who do not? b) Are there
genetic differences in those who develop
sensitization and CBD compared with
those who do not? c) What is the interac-
tion between exposure and genetics that
results in sensitization and CBD? These
questions go beyond CBD, and are impor-
tant for our broader understanding ofhow
environmental and host factors interact in
producing disease (27). Several conclusions
can be drawn thus far from these studies.
First, individuals who are detected by the
BeLPT differ from other workers in their
job titles, tasks, and dates of beryllium
exposure in beryllium industries. There is
an exposure-disease relationship (20,22).
Second, individuals who develop sensiti-
zation and disease share one or more
genetic risk factors for this condition
(16,28). Third, as collaborative work
between groups in Denver and Modena,
Italy shows, beryllium sensitization and
disease are the result of an interaction
between the nature ofthe beryllium expo-
sure and an individual's inheritance.
How should such information be used
in prevention? Even though CBD is a
result of a hypersensitivity to beryllium,
controlling exposure can make a difference.
Armed with information about the types of
jobs and exposures that result in disease,
a company can institute engineering con-
trols that reduce exposures for all workers,
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especially targeting work conditions that
have been identified as hotspots for CBD
in the plant. Will the genetic data allow us
to screen for susceptible workers? It is
unlikely that such genetic tests will prove
useful at this stage in our understanding.
Such tests are not warranted if exposures
can be adequately controlled. Future
research centered on how to reduce the rate
of sensitization and disease in industry
through environmental control is still the
best path to prevention of new cases of
CBD. Medical surveillance with the blood
BeLPT can guide us in assessing the
efficacy ofthese interventions and ofother
preventive strategies.
REFERENCES
1. Curtis GH. Cutaneous hypersensitivity due to beryllium. Arch
Dermatol Syph 64:470-482 (1951).
2. Curtis GH. The diagnosis ofberyllium disease with special ref-
erence to the patch test. Arch Ind Health 19:150-156 (1959).
3. Waksman BH. Discussion of "The diagnosis ofberyllium dis-
ease with special reference to the patch test" by GH Curtis.
Arch Ind Health 19:154-156 (1959).
4. Hanifin JM, Epstein WL, Cline MJ. In vitrostudies ofgranulo-
matous hypersensitivity to beryllium. J Invest Dermatol
55:284-288 (1970).
5. Van Ganse WF, Oleffe J, Van Hove W, Groetenbrie JC.
Lymphocyte transformation in chronic berylliosis. Lancet
1:1023 (1972).
6. Deodhar SD, Barna B, van Ordstrand HS. Astudy ofthe immu-
nologic aspects ofchronic berylliosis. Chest 63:309-313 (1973).
7. Williams WR, Jones Williams W. Comparison oflymphocyte
transformation and macrophage migration inhibition tests in
the detection of beryllium hypersensitivity. J Clin Pathol
35:684-687 (1982).
8. Williams WR, Jones Williams WJ. Development ofberyllium
lymphocyte transformation tests in chronic beryllium disease.
IntArch AllergyAppl Immunol 67:175-180 (1982).
9. Epstein PE, Dauber JH, Rossman MD, Daniele RP.
Bronchoalveolar lavage in a patient with chronic berylliosis: evi-
dence for hypersensitivity pneumonitis. Ann Intern Med
97:213-216 (1982).
10. Jones-Williams W, Williams WR. Value ofberyllium lympho-
cyte transformation tests in chronic beryllium disease and in
potentially exposed workers. Thorax 38:41-44 (1983).
11. Bargon J, Kronenberger H, Bergmann L, Buhl R, Meier-Sydow
J, Mitrou P. Lymphocyte transformation test in a group of
foundry workers exposed to beryllium and non-exposed con-
trols. EurJ Respir Dis 69(Suppl 136):211-215 (1986).
12. Rossman MD, Kern JA, Elias JA, Cullen MR, Epstein PE,
Preuss OP, Markham TN, Daniele RP. Proliferative response
ofbronchoalveolar lymphocytes to beryllium: a test for chronic
beryllium disease. Ann Intern Med 108:687-693 (1988).
13. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening
blood test identifies subclinical beryllium disease. J Occup Med
31:603-608 (1989).
14. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG.
Maintenance of alveolitis in patients with chronic beryllium
disease by beryllium-specific helper T cells. N Engl J Med
320:1103-1109 (1989).
15. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS.
Re-examination ofthe blood lymphocyte transformation test in
the diagnosis of chronic beryllium disease. J Allergy Clin
Immunol 88:54-60 (1991).
16. Kreiss K, Miller F, Newman LS, Ojo-Amaize EA, Rossman
MD, Saltini C. Chronic beryllium disease: from the workplace
to cellular immunology, molecular immunogenetics, and Sack.
Clin Immunol Immunopathol 71:123-129 (1994).
17. Newman LS. Beryllium lung disease: the role ofcell-mediated
immunity in pathogenesis. In: Immunotoxicology and
Immunopharmacology (Dean JH, Luster MI, Munson AE,
Kimber I, eds). New York:Raven Press, 1994;377-393.
18. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA.
Pathologic and immunologic alterations in early stages ofberyl-
lium disease: re-examination of disease definition and natural
history. Am Rev Respir Dis 139:1479-1486 (1989).
19. Newman LS, Mroz MM, Schumacher B, DaniloffE, Kreiss K.
Beryllium sensitization precedes chronic beryllium disease. Am
Rev Respir Dis 145(Suppl):A324 (1992).
20. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium dis-
ease screening in the ceramics industry: blood test performance
and exposure-disease relations. J Occup Med 35:267-274
(1993).
21. Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B,
Mroz MM, King TE Jr. Compartmentalized immune response
reflects clinical severity of beryllium disease. Am J Respir Crit
Care Med 150:135-142 (1994).
22. Kreiss K, Mroz MM, Zhen B, Martyny J, Newman LS.
Epidemiology of beryllium sensitization and disease in nuclear
workers. Am Rev Respir Dis 148:985-991 (1993).
23. Newman LS, Kreiss K. Non-occupational chronic beryllium
disease masquerading as sarcoidosis: identification by blood
lymphocyte proliferative response to beryllium. Am Rev Respir
Dis 145:1212-1214 (1992).
24. Preuss OP, Deodhar SD, van Ordstrand HS. Lymphoblast
transformation in beryllium workers. In: Proceedings of the
Eighth International Conference on Sarcoidosis and other
Granulomatous Diseases, Cardiff, Wales, 1980. (Jones
Williams W, Davies BH, eds). Cardiff, Wales:Alpha Omega,
1980;711-714.
25. Newman LS, Lloyd J, DaniloffE. The natural history ofberyl-
lium sensitization and chronic beryllium disease, 1994. Environ
Health Perspect 104(Suppl 5):937-943 (1996).
26. Pappas GP, Newman LS. Early pulmonary physiologic abnor-
malities in beryllium disease. Am Rev Respir Dis 148:661-666
(1993).
27. Newman LS. To Be2+ or not to Be2+: relating immunogenetics
to occupational exposure. Science 262:197-198 (1993).
28. Richeldi L, Sorrentino R, Saltini C. HLA-DPJ1 glutamate 69:
a genetic marker of beryllium disease. Science 262:242-244
(1993).
956 Environmental Health Perspectives X Vol 104, Supplement 5 * October 1996